Genmab A/S - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GMAB Nasdaq 2830 www.genmab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab - Jun 12th, 2025 11:08 am
Transactions in Connection with Share Buy-back Program - Jun 10th, 2025 5:23 am
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data - Jun 3rd, 2025 5:48 am
Why Genmab Stock Smashed It on Monday - Jun 2nd, 2025 4:49 pm
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Jun 2nd, 2025 12:30 pm
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital - May 30th, 2025 7:05 am
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference - May 27th, 2025 7:55 am
Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025 - May 22nd, 2025 11:49 pm
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - May 22nd, 2025 3:05 pm
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference - May 21st, 2025 8:02 am
Capital Increase in Genmab as a Result of Employee Warrant Exercise - May 20th, 2025 10:01 am
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress - May 14th, 2025 8:15 am
Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives - May 9th, 2025 1:36 am
Genmab Announces Financial Results for the First Quarter of 2024 - May 8th, 2025 9:01 am
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - May 1st, 2025 6:24 pm
Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now? - May 1st, 2025 1:31 am
GMAB or RGEN: Which Is the Better Value Stock Right Now? - Apr 16th, 2025 9:40 am
Should Value Investors Buy Genmab (GMAB) Stock? - Apr 16th, 2025 7:40 am
Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025 - Apr 15th, 2025 11:43 am
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 - Apr 15th, 2025 4:22 am